Pharmacokinetics, mass balance, and metabolism of [C]PLB1004, a selective and irreversible EGFR-TKI in humans.

Purpose: PLB1004, developed by Beijing Avistone Biotechnology Co., Ltd., is a safe, highly selective, and efficient irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) employed in treating non-small-cell-lung-cancer (NSCLC).

HSF-IBI: A Universal Framework for Extracting Inter-Beat Interval from Heterogeneous Unobtrusive Sensors.

Heartbeat inter-beat interval (IBI) extraction is a crucial technology for unobtrusive vital sign monitoring, yet its precision and robustness remain challenging. A promising approach is fusing heartbeat signals from different types of unobtrusive sensors. This paper introduces HSF-IBI, a novel and universal framework for unobtrusive IBI extraction using heterogeneous sensor fusion.

Non-Contact Stable Arterial Pulse Measurement Using mmWave Array Radar.

Pulse signals can serve as important indicators of one's cardiovascular condition. However, capturing signals with stable morphology using radar under varying measurement periods remains a significant challenge. This paper reports a non-contact arterial pulse measurement method based on mmWave radar, with stable signals achieved through a range-angle focusing algorithm.

Research note: Proteomics profiling reveal key proteins in egg white emulsification.

Egg white proteins are widely recognized as excellent natural emulsifiers, yet the molecular mechanisms underlying their emulsification properties remain incompletely understood, particularly regarding the roles of individual proteins in complex natural systems. Using 4D-label-free quantitative proteomics, we systematically investigated protein dynamics during egg white emulsification by comparing egg white (EW) and the aqueous phases of egg white emulsions (EWE-W). Proteomic analysis identified 96 distinct proteins, with 64 showing significant abundance changes during emulsification.

Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD-L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy.

Programmed death protein-ligand 1 (PD-L1) inhibitors demonstrate significant antitumor efficacy by modulating T-cell activity and inhibiting the PD-1/PD-L1 pathway, thus enhancing immune responses. Despite their robust effects, systemic administration of these inhibitors is linked to severe immune toxicity. To address this issue, we engineered a strain, REP, which releases PD-L1 nanoantibodies (PD-L1nb) to treat breast cancer and attenuate immunotherapy-related side effects.